Rani Therapeutics (US:RANI)2025-11-06 21:30Financial Performance - The company completed a $60.3 million oversubscribed private placement, reducing total debt obligations and enhancing financial stability [5]. - Cash, cash equivalents, and marketable securities as of September 30, 2025, totaled $4.1 million, down from $27.6 million at the end of 2024, but expected to fund operations into 2028 [10]. - Net loss for Q3 2025 was $7.9 million, compared to $12.7 million for the same period in 2024, reflecting improved financial performance [10]. - Total liabilities as of September 30, 2025, were $22.1 million, down from $33.1 million at the end of 2024, indicating improved financial health [14]. Research and Development - Research and development expenses for Q3 2025 were $3.2 million, a decrease of $3.0 million compared to $6.2 million in Q3 2024 [10]. - The company plans to initiate a Phase 1 clinical trial for RT-114, a novel oral therapy targeting obesity, by the end of 2025 [7]. - Preclinical data presented at ObesityWeek® 2025 showed that oral semaglutide delivered via RaniPill® demonstrated comparable bioavailability and weight loss to subcutaneous administration [6]. Corporate Governance - Abraham Bassan and Vasudev Bailey, Ph.D., were appointed to the Board of Directors, enhancing the company's governance [5]. Collaboration and Licensing - Rani Therapeutics entered into a collaboration and license agreement with Chugai Pharmaceutical Co. valued at up to $1.085 billion to develop an oral therapy [5]. Operating Expenses - General and administrative expenses for Q3 2025 were $4.0 million, down from $5.6 million in Q3 2024, primarily due to lower compensation costs [10].